Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGER | Q15109 | 11/20 | 1.00 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 7/20 | 0.42 |
| ▸ | LTA4H | P09960 | 2/20 | 0.41 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12203916 | 0.89 | AGER (0.80) | AGERPTGS1SLC6A4 | |
| SCHEMBL23631278 | 0.88 | AGER (1.00) | AGERSLC6A4 | |
| SCHEMBL1576986 | 0.87 | AGER (0.77) | AGERPTGS1LTA4H | |
| SCHEMBL3508025 | 0.85 | AGER (0.86) | AGER | |
| SCHEMBL18650027 | 0.85 | AGER (0.86) | AGER | |
| SCHEMBL23631263 | 0.84 | AGER (1.00) | AGERSLC6A4LTA4H | |
| SCHEMBL18650011 | 0.84 | AGER (0.79) | AGERSLC6A4 | |
| SCHEMBL1283582 | 0.83 | AGER (0.72) | AGERPTGS1LTA4H | |
| SCHEMBL1576892 | 0.83 | AGER (0.72) | AGERSLC6A4 | |
| SCHEMBL1283217 | 0.83 | AGER (0.71) | AGERPTGS1LTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11970457-B2 | Metabolites of [3-(4-(2-butyl-1-[4-(4-chloro-phenoxy)-phenyl]-1H-imidazol-4-yl)-phenoxy)-propyl]-diethyl-amine | VTV THERAPEUTICS LLC (US) | 2024-04-30 | — | — | US | claimed |
| US-20230183183-A1 | METABOLITES OF [3-(4-(2-BUTYL-1-[4-(4-CHLORO-PHENOXY)-PHENYL]-1H-IMIDAZOL-4 YL)-PHENOXY)-PROPYL]-DIETHYL-AMINE | VTV THERAPEUTICS LLC | 2023-06-15 | — | — | US | claimed |
| EP-3864008-A1 | METABOLITES OF [3-(4-{2-BUTYL-L-[4-(4-CHLORO-PHENOXY)-PHENYL]-LH-IMIDAZOL-4-YL } -PHEN OX Y)-PROP YL] -DIETHYL-AMINE | vTv Therapeutics LLC (US) | 2021-08-18 | — | — | EP | claimed |
| US-20210214314-A1 | METABOLITES OF [3-(4-{2-BUTYL-1-[4-(4-CHLORO-PHENOXY)-PHENYL]-1H-IMIDAZOL-4 YL}-PHENOXY)-PROPYL]-DIETHYL-AMINE | VTV THERAPEUTICS LLC | 2021-07-15 | — | — | US | claimed |
| US-10363241-B2 | Substituted imidazole derivatives and methods of use thereof | VTV THERAPEUTICS LLC (US) | 2019-07-30 | — | — | US | claimed |
| US-20190076402-A1 | Substituted Imidazole Derivatives and Methods of Use Thereof | TRANSTECH PHARMA, INC. | 2019-03-14 | — | — | US | claimed |
| US-11970457-B2 | Metabolites of [3-(4-(2-butyl-1-[4-(4-chloro-phenoxy)-phenyl]-1H-imidazol-4-yl)-phenoxy)-propyl]-diethyl-amine | VTV THERAPEUTICS LLC (US) | 2024-04-30 | — | — | US | disclosed |
| US-20230183183-A1 | METABOLITES OF [3-(4-(2-BUTYL-1-[4-(4-CHLORO-PHENOXY)-PHENYL]-1H-IMIDAZOL-4 YL)-PHENOXY)-PROPYL]-DIETHYL-AMINE | VTV THERAPEUTICS LLC | 2023-06-15 | — | — | US | disclosed |
| US-20230183183-A1 | METABOLITES OF [3-(4-(2-BUTYL-1-[4-(4-CHLORO-PHENOXY)-PHENYL]-1H-IMIDAZOL-4 YL)-PHENOXY)-PROPYL]-DIETHYL-AMINE | VTV THERAPEUTICS LLC | 2023-06-15 | — | — | US | disclosed |
| US-20230183183-A1 | METABOLITES OF [3-(4-(2-BUTYL-1-[4-(4-CHLORO-PHENOXY)-PHENYL]-1H-IMIDAZOL-4 YL)-PHENOXY)-PROPYL]-DIETHYL-AMINE | VTV THERAPEUTICS LLC | 2023-06-15 | — | — | US | disclosed |
| US-11524942-B2 | Metabolites of [3-(4-{2-butyl-1-[4-(4-chloro-phenoxy)-phenyl]-1H-imidazol-4 yl}-phenoxy)-propyl]-diethyl-amine | VTV THERAPEUTICS LLC (US) | 2022-12-13 | — | — | US | disclosed |
| US-11524942-B2 | Metabolites of [3-(4-{2-butyl-1-[4-(4-chloro-phenoxy)-phenyl]-1H-imidazol-4 yl}-phenoxy)-propyl]-diethyl-amine | VTV THERAPEUTICS LLC (US) | 2022-12-13 | — | — | US | disclosed |
| EP-3864008-A1 | METABOLITES OF [3-(4-{2-BUTYL-L-[4-(4-CHLORO-PHENOXY)-PHENYL]-LH-IMIDAZOL-4-YL } -PHEN OX Y)-PROP YL] -DIETHYL-AMINE | vTv Therapeutics LLC (US) | 2021-08-18 | — | — | EP | disclosed |
| US-20110105578-A1 | Substituted Imidazole Derivatives And Methods Of Use Thereof | VTV THERAPEUTICS LLC | 2011-05-05 | — | — | US | disclosed |
| WO-2011041198-A1 | SUBSTITUTED IMIDAZOLE DERIVATIVES FOR TREATMENT OF ALZHEIMERS DISEASE | TRANSTECH PHARMA, INC. (US) | 2011-04-07 | — | — | WO | disclosed |
| WO-2011041198-A1 | SUBSTITUTED IMIDAZOLE DERIVATIVES FOR TREATMENT OF ALZHEIMERS DISEASE | TRANSTECH PHARMA, INC. (US) | 2011-04-07 | — | — | WO | disclosed |
| US-7884219-B2 | Receptor antagonist of advanced glycosylation endproducts ; antiinflammatory agents; Alzheimer's disease; anticancer, antitumor agent; autoimmune disease; antiarthritic agents; multiple sclerosis; diabetic nephropathy; cardiovascular disorders; osteoporosis | TRANSTECH PHARMA, INC. (US) | 2011-02-08 | — | — | US | disclosed |
| EP-2144883-A1 | CRYSTALLINE FORMS I AND II OF [3-(4-{2-BUTYL-1-[4-(4-CHLORO-PHENOXY)-PHENYL]-1H-IMIDAZOL-4-YL}-PHENOXY)-PROPYL]-DIETHYL-AMINE | TransTech Pharma, Inc (US) | 2010-01-20 | — | — | EP | disclosed |
| WO-2008123914-A1 | CRYSTALLINE FORMS I AND II OF [3-(4-{2-BUTYL-1-[4-(4-CHLORO-PHENOXY)-PHENYL]-1H-IMIDAZOL-4-YL}-PHENOXY)-PROPYL]-DIETHYL-AMINE | TRANSTECH PHARMA, INC. (US) | 2008-10-16 | — | — | WO | disclosed |
| US-20080249316-A1 | CRYSTALLINE FORMS OF [3-(4- -PHENOXY)-PROPYL]-DIETHYL-AMINE | VTV THERAPEUTICS LLC | 2008-10-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190076402-A1 | Substituted Imidazole Derivatives and Methods of Use Thereof | CYP3A7, CYP3A5, CYP3A43 | AGER 3594/4885PTGS1 409/4885SLC6A4 273/4885 |
| US-10363241-B2 | Substituted imidazole derivatives and methods of use thereof | CYP3A7, CYP3A5, CYP3A43 | AGER 3594/4885PTGS1 409/4885SLC6A4 273/4885 |
| US-11524942-B2 | Metabolites of [3-(4-{2-butyl-1-[4-(4-chloro-phenoxy)-phenyl]-1H-imidazol-4 yl}-phenoxy)-propyl]-diethyl-amine | AGER, GPR174, P2RY4 | AGER 1/4885PTGS1 758/4885SLC6A4 397/4885 |
| US-20210214314-A1 | METABOLITES OF [3-(4-{2-BUTYL-1-[4-(4-CHLORO-PHENOXY)-PHENYL]-1H-IMIDAZOL-4 YL}-PHENOXY)-PROPYL]-DIETHYL-AMINE | AGER, GPR174, P2RY4 | AGER 1/4885PTGS1 758/4885SLC6A4 397/4885 |
| US-20110105578-A1 | Substituted Imidazole Derivatives And Methods Of Use Thereof | AGER, NOD2, PSEN1 | AGER 1/4885PTGS1 164/4885SLC6A4 1234/4885 |
| US-11970457-B2 | Metabolites of [3-(4-(2-butyl-1-[4-(4-chloro-phenoxy)-phenyl]-1H-imidazol-4-yl)-phenoxy)-propyl]-diethyl-amine | AGER, GPR174, P2RY4 | AGER 1/4885PTGS1 689/4885SLC6A4 729/4885 |
| US-20230183183-A1 | METABOLITES OF [3-(4-(2-BUTYL-1-[4-(4-CHLORO-PHENOXY)-PHENYL]-1H-IMIDAZOL-4 YL)-PHENOXY)-PROPYL]-DIETHYL-AMINE | AGER, GPR174, P2RY4 | AGER 1/4885PTGS1 756/4885SLC6A4 407/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.